Betting Markets on FDA Decisions Unsettle Medical Researchers
Source: The New York Times
The emergence of regulated prediction markets like Kalshi and Polymarket has created a conflict-of-interest vector: financial incentives now shadow critical FDA approval decisions. If researchers or their institutions can profit from specific regulatory outcomes, the separation between objective science and market speculation erodes. Researchers may face pressure to alter trial design, data interpretation, or publication decisions to move market prices. Regulators and medical bodies have largely treated prediction markets as neutral information aggregators rather than active financial actors with real consequences for institutional behavior.